CClinicalTrials.gg
Sign In
RecruitingNCT07481396PCABI-OMICSUpdated Mar 18, 2026

Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics

An observational study in Cardiac Arrest (CA), Cerebrospinal Fluid and Multiomics, sponsored by Chungnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Chungnam National University Hospital · Observational

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques.

The main question this study aims to answer is:

Which genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest?

To address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.

02

Conditions studied

  • Cardiac Arrest (CA)
  • Cerebrospinal Fluid
  • Multiomics
  • Hypoxic-Ischemic Brain Injury
03

In context

Heart Arrest

966 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

This study's planned enrollment of 60 is below the median of 200 across 383 observational studies indexed under Heart Arrest.

Browse Heart Arrest studies →

Lead sponsor

Chungnam National University Hospital is the lead sponsor of 20 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population for this research consists of a highly specific and clinically critical group of patients: Adults who have experienced out-of-hospital or in-hospital cardiac arrest and successfully regained spontaneous circulation (ROSC), but remain at high risk for secondary brain injury.

Inclusion criteria

  • Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment.
  • Patients without contraindications for lumbar puncture catheter insertion for cerebrospinal fluid (CSF) collection. This includes the absence of:
  • Uncontrolled diabetes.Coagulation disorders.
  • Thrombocytopenia (platelet count $\< 100,000).
  • A history of cirrhosis diagnosis.
  • Current receipt of low molecular weight heparin.
  • Current use of platelet inhibitors.
  • A history of posterior spinal fusion that may interfere with catheter insertion.
  • Local skin infection or rash at the puncture site.
  • Signs of systemic infection or sepsis.
  • A history of lumbar puncture within the past 6 hours.

Exclusion criteria

Exclusion Criteria:

  • Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery.
  • Patients who underwent extracorporeal membrane oxygenation (ECMO).
  • Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest.
  • Patients with a history of acute or chronic brain disease.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Favorable neurological outcome

    The favorable neurological outcome group is classified as patients with a CPC score of 1 or 2 upon long-term follow-up (at discharge, 3 months after post-resuscitation)

  • Unfavorable neurological outcome

    The favorable neurological outcome group is classified as patients with a CPC score of 3 to 5 upon long-term follow-up (at discharge, 3 months after post-resuscitation)

06

What researchers measure

Primary outcomes

  1. Neurological outcome

    Neurological outcome assessed using the Cerebral Performance Category (CPC) scale (range 1-5; lower scores indicate better neurological function).

    Time frame: at discharge (assessed up to 3 days), 3 months after return of spontaneous circulation (ROSC)

07

Study locations

1 of 1 sites recruiting
  • Chungnam National University Hospital
    Daejeon, Jung-gu 35015, South Korea
    Recruiting
08

References and documents

Publications

  • Edgren E, Enblad P, Grenvik A, Lilja A, Valind S, Wiklund L, Hedstrand U, Stjernstrom H, Persson L, Ponten U, Langstrom B. Cerebral blood flow and metabolism after cardiopulmonary resuscitation. A pathophysiologic and prognostic positron emission tomography pilot study. Resuscitation. 2003 May;57(2):161-70. doi: 10.1016/s0300-9572(03)00004-2. PubMed 12745184 ↗
  • Buunk G, van der Hoeven JG, Meinders AE. Cerebral blood flow after cardiac arrest. Neth J Med. 2000 Sep;57(3):106-12. doi: 10.1016/s0300-2977(00)00059-0. No abstract available. PubMed 10978556 ↗
  • Madl C, Holzer M. Brain function after resuscitation from cardiac arrest. Curr Opin Crit Care. 2004 Jun;10(3):213-7. doi: 10.1097/01.ccx.0000127542.32890.fa. PubMed 15166839 ↗
  • Wiklund L, Martijn C, Miclescu A, Semenas E, Rubertsson S, Sharma HS. Central nervous tissue damage after hypoxia and reperfusion in conjunction with cardiac arrest and cardiopulmonary resuscitation: mechanisms of action and possibilities for mitigation. Int Rev Neurobiol. 2012;102:173-87. doi: 10.1016/B978-0-12-386986-9.00007-7. PubMed 22748830 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07481396
Lead sponsor
Chungnam National University Hospital
Responsible party
Changshin Kang (Assistant professor, Chungnam National University Hospital) — Principal investigator
First posted
Mar 18, 2026
Start date
Dec 1, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Mar 18, 2026

Study contacts

Changshin Kang, MD. PhD
Contact
rosc@cnu.ac.kr
+821089928386

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Heart Arrest→

Other studies from this sponsor

Chungnam National University Hospital

Start the discussion